BlossomHill Therapeutics (NASDAQ:BLSM) Upgraded at HC Wainwright

BlossomHill Therapeutics (NASDAQ:BLSM) was upgraded by equities researchers at HC Wainwright to a “strong-buy” rating in a report released on Tuesday, Zacks reports.

Other research analysts have also recently issued research reports about the stock. Guggenheim began coverage on shares of BlossomHill Therapeutics in a report on Tuesday. They set a “buy” rating and a $30.00 target price for the company. Lifesci Capital began coverage on shares of BlossomHill Therapeutics in a research report on Tuesday. They set an “outperform” rating and a $32.00 price target on the stock. Leerink Partners assumed coverage on shares of BlossomHill Therapeutics in a research note on Tuesday. They set an “outperform” rating and a $36.00 price objective for the company. Wall Street Zen upgraded BlossomHill Therapeutics to a “hold” rating in a report on Saturday, August 15th. Finally, JPMorgan Chase & Co. assumed coverage on BlossomHill Therapeutics in a research report on Tuesday. They issued an “overweight” rating and a $28.00 target price on the stock. Three research analysts have rated the stock with a Strong Buy rating and two have assigned a Buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Strong Buy” and an average price target of $32.20.

BlossomHill Therapeutics Stock Performance

Shares of BLSM opened at $18.99 on Tuesday. BlossomHill Therapeutics has a twelve month low of $15.25 and a twelve month high of $20.61.

Insider Buying and Selling

In other news, General Counsel Vincent Paul Liptak bought 2,200 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The stock was acquired at an average cost of $16.00 per share, for a total transaction of $35,200.00. Following the purchase, the general counsel owned 111,412 shares of the company’s stock, valued at approximately $1,782,592. This trade represents a 2.01% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director John P. Schmid purchased 6,000 shares of BlossomHill Therapeutics stock in a transaction that occurred on Monday, August 10th. The shares were acquired at an average price of $16.00 per share, with a total value of $96,000.00. Following the acquisition, the director directly owned 6,000 shares of the company’s stock, valued at $96,000. This trade represents a ∞ increase in their position. The SEC filing for this purchase provides additional information. Insiders purchased 1,573,900 shares of company stock worth $25,181,900 in the last 90 days.

About BlossomHill Therapeutics

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company’s lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.